TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia

Clinical Cancer Research

Volumn 10, Issue 16, 2004, Pages 5355-5360

  Zuna, Jan ^a,b   Ford, Anthony M ^a   Peham, Martina ^c   Patel, Naina ^d   Saha, Vaskar ^d   Eckert, Cornelia ^e   Köchling, Joachim ^e   Panzer Grümayer, Renate ^c   Trka, Jan ^b   Greaves, Mel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FUSION GENE; GENE DELETION; GENE MAPPING; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC DISORDER; HUMAN; LEUKEMIA REMISSION; MICROSATELLITE MARKER; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE RECEPTOR GENE; TEL AML1 FUSION GENE; TEL GENE;

ARTIFICIAL GENE FUSION; CHILD; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DATABASES, GENETIC; DNA-BINDING PROTEINS; GENE REARRANGEMENT, T-LYMPHOCYTE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MICROSATELLITE REPEATS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; RECURRENCE; REPRESSOR PROTEINS; SEQUENCE DELETION; TRANSCRIPTION FACTORS;

EID: 4143127775     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0584     Document Type: Article

References (33)

1. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997;90:571-7.
2. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996;88:4252-8.
3. Romana SP, Poirel H, Leconiat M, et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995;86: 4263-9.
4. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995;9:1985-9.
5. The United Kingdom Childhood Cancer study: objectives, materials and methods. UK Childhood Cancer Study Investigators. Br J Cancer 2000;82:1073-102.
6. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA 1998;95:4584-8.
7. Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 1999;94:1057-62.
8. Maia AT, Ford AM, Jalali GR, et al. Molecular tracking of leukemogenesis in a triplet pregnancy. Blood 2001;98:478-82.
9. Hjalgrim LL, Madsen HO, Melbye M, et al. Presence of clone-specific markers at birth in children with acute lymphoblastic leukaemia. Br J Cancer 2002;87:994-9.
10. McHale CM, Wiemels JL, Zhang L, et al. Prenatal origin of TEL-AML1-positive acute lymphoblastic leukemia in children born in California. Genes Chromosomes Cancer 2003;37:36-43.
11. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999;354:1499-503.
12. Cave H, Cacheux V, Raynaud S, et al. ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. Leukemia (Baltimore) 1997;11:1459-64.
13. Kempski H, Chalker J, Chessells J, et al. An investigation of the t(12;21) rearrangement in children with B-precursor acute lymphoblastic leukaemia using cytogenetic and molecular methods. Br J Haematol 1999;105:684-9.
14. Raynaud S, Cave H, Baens M, et al. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996;87:2891-9.
15. Aissani B, Sinnett D. Fine physical and transcript mapping of a 1.8 Mb region spanning the locus for childhood acute lymphoblastic leukemia on chromosome 12p12. 3. Gene (Amst) 1999;240:297-305.
16. Baens M, Wlodarska I, Corveleyn A, Hoornaert I, Hagemeijer A, Marynen P. A physical, transcript, and deletion map of chromosome region 12p12.3 flanked by ETV6 and CDKNIB: hypermethylation of the LRP6 CpG island in two leukemia patients with hemizygous del(12p). Genomics 1999;56:40-50.
17. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002;99:8242-7.
18. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002;2:502-13.
19. Greaves, M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer 1999;35:1941-53.
20. Seeger K, Stackelberg AV, Taube T, et al. Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J Clin Oncol 2001;19:3188-93.
21. Ford AM, Fasching K, Panzer-Grumayer ER, Koenig M, Haas OA, Greaves MF. Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood 2001;98:558-64.
22. Baccichet A, Sinnett D. Frequent deletion of chromosome 12p12.3 in children with acute lymphoblastic leukaemia. Br J Haematol 1997; 99:107-14.
23. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia (Baltimore) 1999;13:110-8.
24. Szczepanski T, Willemse MJ, van Wering ER, van Weerden JF, Kamps WA, van Dongen JJ. Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia (Baltimore) 2001;15:1415-23.
25. Langerak AW, Szczepanski T, van der Burg M, Wolvers-Tettero IL, van Dongen JJ. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia (Baltimore) 1997;11:2192-9.
26. Wiemels JL, Greaves M. Structure and possible mechanisms of TEL-AML1 gene fusions in childhood acute lymphoblastic leukemia. Cancer Res 1999;59:4075-82.
27. Peham M, Konrad M, Harbott J, Konig M, Haas OA, Panzer-Grumayer ER. Clonal variation of the immunogenotype in relapsed ETV6/RUNX1-positive acute lymphoblastic leukemia indicates subclone formation during early stages of leukemia development. Genes Chromosomes Cancer 2004;39:156-60.
28. Konrad M, Metzler M, Panzer S, et al. Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. Blood 2003;101:3635-40.
29. Takeuchi S, Seriu T, van Dongen JJ, et al. Allelotype analysis in relapsed childhood acute lymphoblastic leukemia. Oncogene 2003;22: 6970-6.
30. Kusec R, Laczika K, Knobl P, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia (Baltimore) 1994;8:735-9.
31. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996;87: 4789-96.
32. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993;82:712-5.
33. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003;3:639-49.